
Welcome to our global network Unilabs Netherlands!
Unilabs Netherlands is one of the country’s leading diagnostic healthcare providers, offering a comprehensive range of laboratory, imaging, pathology and specialized services through a large network of labs and sample‐collection points to make reliable diagnostics accessible to patients and providers.
They will leverage SOPHiA DDM™ to analyze inherited and rare disorders to find clarity for some of the most complex genetic cases. They join over 800 institutions who are harnessing the power of AI and data-driven medicine to advance precision care.
Learn more about our Inherited and Rare Disorder solutions: https://www.sophiagenetics.com/sophia-ddm-for-genomics/inherited-disorders/
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.